The European Investment Bank and Orano have signed a €125 million credit line to support the development of Orano Med and the expansion of its industrial infrastructure in France.
The financing will help fund construction of the Advanced Thorium Extraction Facility in Bessines-sur-Gartempe, which Orano says will be the first industrial site dedicated to large-scale production of thorium-228. The isotope is a precursor of lead-212, a key component in targeted alpha therapies being developed for cancer treatment.
Orano Med, a Paris-based clinical-stage biotech and subsidiary of the Orano group, is developing lead-212-based therapies and expanding manufacturing capacity in Europe and North America. The new funding is aimed at strengthening its production platform and centralizing a critical part of the therapy supply chain in France.
The deal adds to a broader push in Europe to build domestic capacity around strategic healthcare technologies and advanced industrial infrastructure.
The financing will help fund construction of the Advanced Thorium Extraction Facility in Bessines-sur-Gartempe, which Orano says will be the first industrial site dedicated to large-scale production of thorium-228. The isotope is a precursor of lead-212, a key component in targeted alpha therapies being developed for cancer treatment.
Orano Med, a Paris-based clinical-stage biotech and subsidiary of the Orano group, is developing lead-212-based therapies and expanding manufacturing capacity in Europe and North America. The new funding is aimed at strengthening its production platform and centralizing a critical part of the therapy supply chain in France.
The deal adds to a broader push in Europe to build domestic capacity around strategic healthcare technologies and advanced industrial infrastructure.